Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

In-patient SCC TMS

Pilot Study: Evaluating the Feasibility of Accelerated rTMS Treatment Delivered at Individual Resonant Frequencies for In-patient Subjects Suffering From Major Depressive Disorder

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The investigators are studying the feasibility, safety, and tolerability of administering accelerated repetitive Transcranial magnetic stimulation(a-rTMS) at frequencies other than standard 10 Hz for in-patient Subjects diagnosed with Major Depressive Disorder. Participants will be recruited from the Resnick Neuropsychiatric Hospital. This study will enroll 30 participants who will undergo up to three brain activity recordings, one MRI scan, one TMS procedure to determine the appropriate frequency and intensity for treatment, daily symptom assessments, and 25 TMS treatments. Participants will be asked to participate for up to 2 weeks.

Who May Be Eligible (Plain English)

Who May Qualify: 1. All subjects must be between 18-65 years of age. 2. Must have confirmed diagnosis of moderate to severe Major Depressive Disorder (single or recurrent episode) as defined by a HAM-D score of 17 or higher. 3. Failure to respond to a minimum of 2 trials of antidepressant medication 4. Failure to respond from at least two different agent classes 5. Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count). 6. Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration. 7. Subjects are willing and able to adhere to the accelerated treatment schedule. Who Should NOT Join This Trial: 8. Are mentally or legally incapacitated, unable to give willing to sign a consent form 9. Have an infection or poor skin condition over the scalp where the device will be positioned 10. Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure 11. Diagnosis of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode. 12. Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system. 13. Presence of an implanted magnetic-sensitive medical device present in the body scan, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI.) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. All subjects must be between 18-65 years of age. 2. Must have confirmed diagnosis of moderate to severe Major Depressive Disorder (single or recurrent episode) as defined by a HAM-D score of 17 or higher. 3. Failure to respond to a minimum of 2 trials of antidepressant medication 4. Failure to respond from at least two different agent classes 5. Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count). 6. Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration. 7. Subjects are willing and able to adhere to the accelerated treatment schedule. Exclusion Criteria: 8. Are mentally or legally incapacitated, unable to give informed consent 9. Have an infection or poor skin condition over the scalp where the device will be positioned 10. Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure 11. Diagnosis of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode. 12. Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system. 13. Presence of an implanted magnetic-sensitive medical device present in the body scan, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI.)

Treatments Being Tested

DEVICE

Open-label TMS

Customized, Open-Label Transcranial Magnetic Stimulation

Locations (1)

UCLA TMS Service and Research Service
Los Angeles, California, United States